Phase 2 Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

This study is testing a medicine called cabozantinib to see if it can help prevent high-risk childhood cancers from coming back after treatment. It aims to offer new options for patients with limited choices by blocking the proteins that help cancer cells grow and spread.

This study is open to people between 18 months and 39 years old who have specific solid tumors. You must be well enough to carry out daily activities and have finished any previous cancer treatments within the required timeframe.

Participants will take cabozantinib as a maintenance therapy, which is a treatment designed to keep cancer away after initial therapy is done. Researchers will carefully monitor your health and how your body responds to the medicine to see if it keeps the cancer from returning.

The study is currently recruiting patients at locations in Birmingham, Alabama; Aurora, Colorado; and Washington, D.C. Because it is a clinical trial, you would be working closely with a medical team at one of these centers.